JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

13.51 2.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.92

Max

13.51

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.989 49.8
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+50.38% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.3B
Ankstesnė atidarymo kaina	11.01
Ankstesnė uždarymo kaina	13.51

Naujienos nuotaikos

By Acuity

50%

180 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

14.24 / 14.78 Palaikymas ir pasipriešinimas

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-05 23:43; UTC

Svarbiausios naujienos

New Zealand's Unemployment Rate Falls in 1Q

2026-05-05 23:20; UTC

Karštos akcijos

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

2026-05-05 21:48; UTC

Uždarbis

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

2026-05-05 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

2026-05-06 00:00; UTC

Rinkos pokalbiai

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

2026-05-05 23:39; UTC

Rinkos pokalbiai

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

2026-05-05 22:26; UTC

Rinkos pokalbiai

AMD Data-Center Business Continues to Surge -- Market Talk

2026-05-05 22:20; UTC

Rinkos pokalbiai

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

2026-05-05 22:08; UTC

Uždarbis

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

2026-05-05 22:07; UTC

Uždarbis

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Adj EPS $1.09 >PAAS

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Rev $1.2B >PAAS

2026-05-05 21:42; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:38; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:30; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:29; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:26; UTC

Uždarbis

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q EPS 39c >ALC.EB

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q Rev $2.71B >ALC.EB

2026-05-05 21:24; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:18; UTC

Uždarbis

Mistras Backs 2026 Rev $730M-$750M >MG

2026-05-05 21:17; UTC

Uždarbis

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

2026-05-05 21:15; UTC

Uždarbis

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

2026-05-05 21:12; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

2026-05-05 21:11; UTC

Uždarbis

SSR Mining 1Q Rev $581.8M >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q Adj EPS $1.15 >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q EPS $1.16 >SSRM

2026-05-05 21:08; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:01; UTC

Uždarbis

Intact Financial 1Q EPS C$4.12 >IFC.T

2026-05-05 21:01; UTC

Karštos akcijos

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

50.38% į viršų

12 mėnesių prognozė

Vidutinis 20 USD 50.38%

Aukščiausias 20 USD

Žemiausias 20 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

180 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.